Literature DB >> 32595007

Association Between Plasma Trimethylamine N-oxide and Neoatherosclerosis in Patients With Very Late Stent Thrombosis.

Yu Tan1, Jinying Zhou2, Chen Liu2, Peng Zhou2, Zhaoxue Sheng2, Jiannan Li2, Runzhen Chen2, Li Song2, Hanjun Zhao2, Bo Xu2, Runlin Gao2, Hongbing Yan3.   

Abstract

BACKGROUND: Trimethylamine N-oxide (TMAO) has been shown to promote the development of atherosclerosis. However, the relationship between plasma TMAO and neoatherosclerosis, an important underlying mechanism of very late stent thrombosis (VLST), is unknown.
METHODS: This post hoc study investigated the association between TMAO and neoatherosclerosis in 2 independent cohorts. These included a control group of 50 healthy volunteers and a study cohort of 50 patients with VLST who presented with ST-segment elevation myocardial infarction and underwent optical coherence tomography examination. Of the 50 patients with VLST, 23 had neoatherosclerosis and 27 did not have neoatherosclerosis. Patients with neoatherosclerosis were further divided into 2 subgroups, including 14 patients with plaque rupture and 9 without plaque rupture.
RESULTS: The plasma TMAO levels, detected using mass spectrometry, were significantly higher in patients with VLST than in healthy individuals (median [interquartile range], 2.50 [1.67-3.84] vs 1.32 [0.86-2.44] μM; P < 0.001). Among the patients with VLST, the plasma TMAO levels were significantly higher in patients with neoatherosclerosis than in those without neoatherosclerosis (3.69 [2.46-5.29] vs 1.96 [1.39-2.80] μM; P < 0.001). In addition, in patients with neoatherosclerosis, patients with plaque rupture had significantly higher plasma TMAO concentrations than those without plaque rupture (4.51 [3.41-5.85] vs 2.46 [2.05-3.55] μM; P = 0.005). Multivariate analysis indicated that TMAO was an independent predictor of neoatherosclerosis (odds ratio, 3.41; 95% confidence interval, 1.59-7.30; P = 0.002). Moreover, the area under the receiver operating characteristic curve for TMAO, differentiated by neoatherosclerosis, was 0.85.
CONCLUSIONS: Plasma TMAO was significantly correlated with neoatherosclerosis and plaque rupture in patients with VLST.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 32595007     DOI: 10.1016/j.cjca.2019.10.041

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

1.  Trimethylamine N-Oxide, a Gut Microbiota-Dependent Metabolite, is Associated with Frailty in Older Adults with Cardiovascular Disease.

Authors:  Wei He; Yao Luo; Jun-Peng Liu; Ning Sun; Di Guo; Ling-Ling Cui; Pei-Pei Zheng; Si-Min Yao; Jie-Fu Yang; Hua Wang
Journal:  Clin Interv Aging       Date:  2020-09-30       Impact factor: 4.458

2.  Gut microbiota in sarcopenia and heart failure.

Authors:  Chia-Feng Liu; W H Wilson Tang
Journal:  J Cardiovasc Aging       Date:  2022-07-05

3.  Culprit-Plaque Morphology and Residual SYNTAX Score Predict Cardiovascular Risk in Acute Myocardial Infarction: An Optical Coherence Tomography Study.

Authors:  Ying Wang; Xiaoxiao Zhao; Peng Zhou; Chen Liu; Zhaoxue Sheng; Jiannan Li; Jinying Zhou; Runzhen Chen; Yi Chen; Li Song; Hanjun Zhao; Hongbing Yan
Journal:  J Atheroscler Thromb       Date:  2021-09-19       Impact factor: 4.394

4.  Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis.

Authors:  Yuan Fu; Yixing Yang; Chen Fang; Xinming Liu; Ying Dong; Li Xu; Mulei Chen; Kun Zuo; Lefeng Wang
Journal:  Front Cardiovasc Med       Date:  2022-08-30

5.  Plasma levels of trimethylamine-N-oxide can be increased with 'healthy' and 'unhealthy' diets and do not correlate with the extent of atherosclerosis but with plaque instability.

Authors:  Yen Chin Koay; Yung-Chih Chen; Jibran A Wali; Alison W S Luk; Mengbo Li; Hemavarni Doma; Rosa Reimark; Maria T K Zaldivia; Habteab T Habtom; Ashley E Franks; Gabrielle Fusco-Allison; Jean Yang; Andrew Holmes; Stephen J Simpson; Karlheinz Peter; John F O'Sullivan
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.